.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical consequence of 11 months, clients along with metastatic intestinal cysts who got biomarker-matched therapies based upon distributing lump DNA profiling showed a higher clinical advantage than those obtaining incomparable therapy.